Reported Earlier, Johnson & Johnson's DARZALEX FASPRO Quadruplet Therapy Approved By FDA For Initial Treatment Of Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's DARZALEX FASPRO Quadruplet Therapy has been approved by the FDA for the initial treatment of multiple myeloma. The therapy showed a 60% reduction in the risk of disease progression or death, solidifying it as a foundational frontline therapy.
July 31, 2024 | 7:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's DARZALEX FASPRO Quadruplet Therapy has received FDA approval for the initial treatment of multiple myeloma, demonstrating a 60% reduction in disease progression or death risk.
The FDA approval of DARZALEX FASPRO Quadruplet Therapy for initial treatment of multiple myeloma is a significant milestone for Johnson & Johnson. The therapy's demonstrated 60% reduction in disease progression or death risk is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100